Audited Financial Results and recommendation of final dividend for financial year 2025-26
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported strong FY2025-26 results with consolidated revenue of ₹2,02,299 lakhs, up 37% from ₹1,47,684 lakhs in the previous year. Profit after tax grew 40% to ₹36,400 lakhs from ₹26,011 lakhs, with EPS at ₹283.71 versus ₹202.74 YoY. The Board recommended a final dividend of ₹34 per share (340% on ₹10 face value). Auditors issued unmodified opinions on both standalone and consolidated results with no qualifications or concerns. The company also approved expanding capacity at its Unit 1 by 120.5 KL at an investment of ₹143.4 crores, financed through internal accruals and borrowings. Capacity utilization is currently at 91% with the expansion aimed at meeting growing customer demand. Dr. Mauricio Futran was appointed as Additional Director (Non-Executive Non-Independent).
The company delivered robust double-digit growth in both revenue and profitability, indicating strong operational performance. The dividend declaration and capacity expansion signal confidence in sustained growth, which could be positive for shareholder returns and stock sentiment.